MedTrace Logo

Investigating Healthcare Disparities in Vitiligo

NCT06097494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39374

Last updated 2025-03-17

Study results available
· View outcomes & findings →

Summary

Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are however, limited population-based studies on the burden of vitiligo and disparities across people of different ethnicities and deprivation.

The overall purpose of this study is to provide an estimate of the lifetime risk of vitiligo in the population overall and by sociodemographic subgroups. Moreover, to do a subgroup analysis in the vitiligo population to identify health-related disparities across people in different sex, age, deprivation and ethnicity. A detailed understanding of the burden of disease in different sociodemographic groups is vital to plan resource provision.

Conditions

  • Vitiligo

Interventions

OTHER

No intervention

Observational analysis of usual care only.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Momentum Data

    lead INDUSTRY

Principal Investigators

  • Andrew McGovern, MD · Momentum Data

Eligibility

Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-20
Primary Completion
2024-07-17
Completion
2024-07-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06097494 on ClinicalTrials.gov